Practical experience of using disease-modifying drugs for lumbosacral dorsalgia

Abstract

Pain in the lumbosacral localization occurs in more than 70% of people and the main contingent of those who seek medical help are patients of working age [1]. The causes of its occurrence are degenerative and dystrophic processes of intervertebral discs and facet joints and muscle tonic reactions. Combined disease-modifying drugs (chondroprotectors) are highly effective in the complex treatment of such diseases. In a group of 39 patients, a study was conducted of the efficiency of the use of modern chondroprotector Flexinovo for nonspecific pain in the lower back, 1 tablet per day for 3 months, with an assessment of the patient's condition during 6 months. A statistically significant decrease in pain intensity according to a visual analogue scale is achieved by the end of the course of treatment, with an increase in the effect by the end of the observation from 6.00 (5.00; 6.00), pc-6m <0.001Z, 4.50 (4.00; 6.00), p3m-6m <0.001 and 1.00 (1.00; 2.25), respectively. Also, the intensity of neuropathic pain decreases according to the DN4 scale, with dynamics from the moment of screening (3 (2; 3), pc-3m <0.001) to the end of the drug use (1 (1; 2) and follow-up 1 (1; 2), (p3m-6m = 0.46). During the observation period, there was a positive effect on the quality of life according to the SF-36 scale with an improvement in general health parameters over time from 52 (50; 62) to 72 (72; 77), respectively (p <0.001). Less pronounced improvements were noted in this sample on the scale of emotional functioning - 33.3 (33.3; 66.7) and 66.7 (66.7; 100), accordingly (p <0.001). All the studied patients showed clinically significant satisfaction with the treatment.